At the European Association of Urology Congress in Paris, a recent study was presented unveiling the initial findings of the first long-term follow-up study on the Uromune (MV140) inactivated vaccine developed by the Madrid-based Immunotek S.L., for recurrent Urinary Tract Infections (UTIs). The study results, disclosed on April 6, 2024, showed that in the extended trial at the Royal Berkshire Hospital in the UK, 89 patients received the vaccine daily for three months and were followed up for nine years.

在巴黎举行的欧洲泌尿外科协会大会上，最近的一项研究揭示了由马德里Immunotek S.L.开发的用于复发性尿路感染（UTI）的尿路免疫（MV140）灭活疫苗的首次长期随访研究的初步结果。2024年4月6日公布的研究结果显示，在英国皇家伯克希尔医院的延长试验中，89名患者每天接种疫苗三个月，随访九年。

Among both male and female participants with recurrent UTIs, 54% remained UTI-free nine years post-vaccination, with no significant side effects reported.The vaccine is administered through two sprays of a pineapple-flavored suspension under the tongue daily for three months and comprises four bacterial species: whole-cell inactivated bacteria, Escherichia coli, Klebsiella pneumoniae, Proteus vulgaris, and Enterococcus faecalis.UTIs are bacterial infections affecting half of women and one in five men, causing a burning sensation during urination and increased frequency.

在复发性尿路感染的男性和女性参与者中，54%在接种疫苗后9年仍无尿路感染，无明显副作用报道。该疫苗每天在舌头下两次喷洒菠萝味悬浮液，持续三个月，由四种细菌组成：全细胞灭活细菌，大肠杆菌，肺炎克雷伯菌，普通变形杆菌和粪肠球菌。泌尿道感染是一种细菌感染，影响一半的女性和五分之一的男性，在排尿时引起灼热感，频率增加。

They pose particular risks to older individuals, and recurrent UTIs develop in 20 to 30% of cases, necessitating short-term antibiotic therapy. However, the rise in antibiotic-resistant infections is reducing the effectiveness of these drugs..

它们对老年人构成特殊风险，复发性UTI在20%至30%的病例中发展，需要短期抗生素治疗。然而，抗生素耐药性感染的增加正在降低这些药物的有效性。。

Dr. Bob Yang, a consultant urologist at the Royal Berkshire NHS Foundation Trust and co-researcher, emphasized the vaccine's long-term safety and efficacy, noting improved UTI severity and frequency. Yang also stated that, 'This is a very easy vaccine to administer and could be given by GPs as a 3-month course.

皇家伯克希尔NHS基金会信托基金会顾问泌尿科医生兼联合研究员鲍勃·杨博士强调了该疫苗的长期安全性和有效性，并指出UTI的严重程度和频率有所改善。杨还表示，“这是一种非常容易接种的疫苗，可以由全科医生进行为期3个月的疗程。

Many of our participants told us that having the vaccine restored their quality of life. While we're yet to look at the effect of this vaccine in different patient groups, this follow-up data suggests it could be a game changer for UTI prevention if it's offered widely, reducing the need for antibiotic treatments.'It's important to note that the vaccine is available off-license in 26 countries, excluding the United States.

我们的许多参与者告诉我们，接种疫苗可以恢复他们的生活质量。虽然我们还没有研究这种疫苗在不同患者群体中的效果，但这一后续数据表明，如果广泛提供这种疫苗，它可能会改变UTI预防的游戏规则，从而减少对抗生素治疗的需求。”值得注意的是，该疫苗在26个国家（不包括美国）无许可证可用。

For comments and feedback contact: editorial@rttnews.comBusiness News.

如需评论和反馈，请联系：editorial@rttnews.comBusiness新闻。

Biotech Stocks Facing FDA Decision In April 2024

2024年4月美国食品和药物管理局决定生物技术股

Biotech Stocks Facing FDA Decision in March 2024

2024年3月美国食品和药物管理局（FDA）决定生物技术股

Biotech Stocks Facing FDA Decision In November 2023

2023年11月美国食品和药物管理局（FDA）决定生物技术股